<DOC>
	<DOCNO>NCT00234403</DOCNO>
	<brief_summary>The progression free survival efficacy 250 mg ZD1839 combination fix dose fulvestrant 250 mg im month evaluate female patient histologically-confirmed advanced metastatic , ER and/or PR positive breast cancer</brief_summary>
	<brief_title>A Trial Evaluate Combination Iressa &amp; FaslodexÂ® Patients With Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Histologically confirm advanced metastatic breast cancer postmenopausal females amenorrhoea &gt; 12 month intact uterus FSH level within postmenopausal range undergone bilateral oophorectomy ER &amp; /or PR positive previous adjuvant hormone therapy &gt; 12 month prior enrolment previous adjuvant chemotherapy &gt; 6 month prior enrolment measurable disease accord RECIST and/or non measurable bone disease life expectancy least 12 week World Health Organisation ( WHO ) performance status ( PS ) 0 1 . Male lifethreatening metastatic visceral disease evidence clinically active interstitial lung disease ER PR negative treatment LHRH analogues &lt; 3 month prior enrolment patient restart menses FSH level within postmenopausal range treatment strontium 90 ( radio pharmaceutical ) within previous 3 month Treatment hormonotherapy and/or chemotherapy advance disease extensive radiotherapy measurable lesion within last 4 week ( i.e . &gt; 30 % bone marrow , e.g . whole pelvis half spine ) currently receive oestrogen replacement therapy treatment nonapproved experimental drug within 4 week enrolment absolute neutrophil count ( ANC ) less 1.5 x 109/litre ( L ) platelets less 100 x 109/L , serum bilirubin great 1.25 time upper limit reference range ( ULRR , serum creatinine great 1.5 mg/dL , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) great 2.5 time ULRR demonstrable liver metastasis , great 5 time ULRR presence liver metastasis , history bleed diathesis long term present anticoagulant therapy ( antiplatelet therapy unresolved chronic toxicity great CTC grade 2 previous anticancer therapy concomitant use phenytoin , carbamazepine , barbiturate , rifampicin , know severe hypersensitivity ZD1839 fulvestrant excipients product .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Advanced breast cancer</keyword>
	<keyword>Metastatic breast cancer</keyword>
	<keyword>ER positive breast cancer</keyword>
	<keyword>PR positive breast cancer</keyword>
</DOC>